Condition: Healthy Volunteers · Sponsor: Prestige Biopharma Limited
The main purpose of the study is to demonstrate pharmacokinetic (PK) equivalence of PBP1502 to the European (EU) and American (US) Humira reference products, following a single subcutaneous (SC) dose of 40 mg in healthy volunteers.
This description comes directly from the study's public registry record.
Sohail Biczadehtakori · +65-6924-6535 · sohail@prestigebio.com
Mandaline Hwee Qi Teo · +65-6924-6535 · mandaline.teo@prestigebio.com
Always discuss trial participation with your own doctor first.
| Unidad de Fase I. U. Autonoma de Madrid (Clinical Trials Unit, UAM) C/ Arzobispo Morcillo 4 | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05108259